Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,753.20
(
-1.57%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
106.58
(
5.89%
)
Bitcoin
71,087.38
(
-3.86%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 174751

Thursday, 09/18/2014 4:50:02 PM

Thursday, September 18, 2014 4:50:02 PM

Post# of 257257
FDA approves LLY’s Trulicity (dulaglutide), a weekly GLP-1 for T2D:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm

Trulicity will compete against NVO’s Victoza and AZN’s Bydureon and Byetta (among other agents).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now